Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TransMedics Group, Inc. (TMDX)
USD73.91
-1.83 (-2.42%)
US NASDAQ Healthcare Medical - Devices
Address
200 Minuteman Road 1810
Andover, MA, US
Andover, MA, US
CEO
Waleed H. Hassanein
Website
transmedics.com
IPO
2019-05-02
CIK 1756262 ISIN US89377M1099
Description
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
News Sentiment (7d)
3 articles
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD73.91
-1.83 (-2.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.88
Float Shares
33.19M
Free Float %
96.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.58% | -11.87% | -43.60% | -50.76% | -44.67% | -47.45% | -47.65% | -14.71% | +195.56% | +185.91% | +185.91% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
73.91
Low
85.00
+15.0%
Consensus
124.33
+68.2%
Median
129.50
+75.2%
High
142.00
+92.1%
Ratings Trend (MoM)
82% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 5 |
122.20
+65.3%
|
| Last Quarter | 6 |
123.50
+67.1%
|
| Last Year | 14 |
137.50
+86.0%
|
| All Time | 35 |
123.97
+67.7%
|
Quality scores
Altman Z-Score
2.27
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+37.1% ★ Q1'26: +21.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+382.2% ★ Q1'26: -71.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+34.3% Q1'26: -7.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+20.0% ★ Q1'26: +7.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+26.7% ★ Q1'26: +5.4% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+15.1% Q1'26: -9.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.16× Q1'26: 8.14× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 6 EPS Ana. |
Dec 2027 9 Rev. Ana. 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
23.60M
est: 24.19M (-2.4%)
|
25.64M
est: 23.98M (+6.9%)
|
30.26M
est: 28.29M (+7.0%)
|
93.46M
est: 86.22M (+8.4%)
|
241.62M
est: 358.76M (-32.7%)
|
441.54M
est: 429.58M (+2.8%)
|
605.49M
est: 600.69M (+0.8%)
|
732.77M
726.94M – 740.17M
+22.0% YoY
|
872.35M
863.45M – 884.38M
+19.0% YoY
|
1.02B
1.01B – 1.03B
+17.0% YoY
|
1.22B
1.20B – 1.24B
+19.1% YoY
|
| EBITDA |
-27.93M
est: -10.09M (-176.7%)
|
-23.15M
est: -10.01M (-131.4%)
|
-38.49M
est: -29.04M (-32.5%)
|
-28.96M
est: -31.94M (+9.3%)
|
-7.70M
est: -67.31M (+88.6%)
|
69.95M
est: -80.60M (+186.8%)
|
148.49M
est: -112.70M (+231.8%)
|
-137.48M
-138.87M – -136.39M
-22.0% YoY
|
-163.67M
-165.93M – -162.00M
-19.0% YoY
|
-191.49M
-192.57M – -190.42M
-17.0% YoY
|
-227.99M
-231.88M – -225.55M
-19.1% YoY
|
| EBIT |
-29.15M
est: -10.95M (-166.2%)
|
-24.73M
est: -10.86M (-127.8%)
|
-40.31M
est: -29.64M (-36.0%)
|
-32.44M
est: -32.60M (+0.5%)
|
-15.88M
est: -78.84M (+79.9%)
|
50.19M
est: -94.41M (+153.2%)
|
121.30M
est: -132.01M (+191.9%)
|
-161.03M
-162.66M – -159.75M
-22.0% YoY
|
-191.71M
-194.35M – -189.75M
-19.0% YoY
|
-224.30M
-225.56M – -223.04M
-17.0% YoY
|
-267.04M
-271.60M – -264.18M
-19.1% YoY
|
| Net Income |
-33.55M
est: -64.92M (+48.3%)
|
-28.75M
est: -42.00M (+31.5%)
|
-44.22M
est: -33.47M (-32.1%)
|
-36.23M
est: -17.78M (-103.7%)
|
-25.03M
est: 3.72M (-771.9%)
|
35.46M
est: 39.73M (-10.7%)
|
190.29M
est: 104.96M (+81.3%)
|
79.56M
64.54M – 109.29M
-24.2% YoY
|
139.18M
113.44M – 186.30M
+74.9% YoY
|
185.66M
167.71M – 260.44M
+33.4% YoY
|
287.64M
283.63M – 294.02M
+54.9% YoY
|
| SGA |
23.60M
est: 18.54M (+27.2%)
|
24.19M
est: 18.38M (+31.6%)
|
38.28M
est: 21.69M (+76.5%)
|
69.90M
est: 32.42M (+115.6%)
|
119.55M
est: 229.28M (-47.9%)
|
168.62M
est: 274.54M (-38.6%)
|
185.17M
est: 383.89M (-51.8%)
|
468.30M
464.58M – 473.03M
+22.0% YoY
|
557.50M
551.82M – 565.20M
+19.0% YoY
|
652.28M
648.61M – 655.95M
+17.0% YoY
|
776.59M
768.27M – 789.84M
+19.1% YoY
|
| EPS |
-2.36
est: -1.84 (-28.0%)
|
-1.16
est: -1.19 (+2.7%)
|
-1.60
est: -1.58 (-1.6%)
|
-1.23
est: -1.33 (+7.3%)
|
-0.77
est: 0.09 (-941.5%)
|
1.07
est: 0.98 (+9.2%)
|
5.60
est: 2.60 (+115.5%)
|
2.11
1.59 – 2.70
-18.7% YoY
|
3.61
2.80 – 4.60
+71.1% YoY
|
5.08
4.14 – 6.42
+40.7% YoY
|
7.10
7.00 – 7.25
+39.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
237.77M
OE per share TTM
5.86
Owner's Yield
10.82%
Maintenance CapEx ratio
257.95%
Maint CapEx / Avg PPE
58.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
95
Total invested
121.08M
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David Abrams | 2.62M | 4.03% | — | 2.62M | — | 2.62M | IN | — | 2021-02-10 | ↗ |
| 2 | Abigail P. Johnson | 2.21M | 6.60% | — | — | 2.21M | — | IN | United States of America | 2024-10-07 | ↗ |
| 3 | FMR LLC | 2.21M | 6.60% | 2.21M | — | 2.21M | — | HC | Delaware | 2024-10-07 | ↗ |
| 4 | (1) BlackRock, Inc. | 1.90M | 6.80% | 1.87M | — | 1.90M | — | HC | Delaware | 2022-02-03 | ↗ |
| 5 | Sandhill Capital Partners LLC d/b/a Sandhill Investment Management | 1.81M | 6.50% | 272.6K | — | 1.81M | — | IA | New York | 2022-02-11 | ↗ |
| 6 | Macquarie Group Limited | 1.65M | 5.95% | — | — | — | — | HC | — | 2022-02-14 | ↗ |
| 7 | Macquarie Investment Management Business Trust | 1.65M | 5.95% | 1.63M | — | 1.63M | — | IA | — | 2022-02-14 | ↗ |
| 8 | Macquarie Management Holdings Inc | 1.65M | 5.95% | 1.63M | — | 1.63M | — | HC | — | 2022-02-14 | ↗ |
| 9 | CREDIT SUISSE AG/000000000 | 1.51M | 5.54% | — | 1.51M | — | 1.51M | BK, HC | — | 2021-02-12 | ↗ |
| 10 | Lung Biotechnology PBC | 1.46M | 6.89% | — | 1.46M | — | — | CO | Delaware | 2020-02-07 | ↗ |
| 11 | United Therapeutics Corporation | 1.46M | 6.89% | — | 1.46M | — | — | CO | Delaware | 2020-02-07 | ↗ |
| 12 | s | — | 0.00% | — | — | — | — | CO | Delaware | 2021-02-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
95
-352 vs prev Q
New positions
21
Closed positions
361
Increased
47
Reduced
25
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 832.2K +832.2K (+100.0%) | 101.24B +101.2B (+100.0%) | 2.44% +2.440 pp | 0.15% +0.153 pp | USD121.65 +0.0% | 1 qtrs NEW |
| 2 | — | 74.6K +74.6K (+100.0%) | 9.07B +9.1B (+100.0%) | 0.22% +0.219 pp | 5.39% +5.388 pp | USD121.65 +0.0% | 1 qtrs NEW |
| 3 | BLACKROCK, INC. | 5.40M +63.6K (+1.2%) | 656.33M +58.1M (+9.7%) | 15.82% +0.095 pp | 0.01% +0.001 pp | USD155.36 -21.7% | 6 qtrs — |
| 4 | FMR LLC | 5.08M +12.7K (+0.3%) | 617.62M +49.4M (+8.7%) | 14.88% -0.050 pp | 0.03% +0.002 pp | USD53.23 +128.5% | 27 qtrs — |
| 5 | VANGUARD GROUP INC | 3.61M -328.0 (0.0%) | 438.58M +34.0M (+8.4%) | 10.57% -0.063 pp | 0.01% +0.000 pp | USD89.65 +35.7% | 27 qtrs — |
| 6 | STATE STREET CORP | 1.28M -4.4K (-0.3%) | 155.12M +11.6M (+8.0%) | 3.74% -0.035 pp | 0.01% +0.000 pp | USD81.06 +50.1% | 27 qtrs — |
| 7 | UBS ASSET MANAGEMENT AMERICAS INC | 996.9K -72.6K (-6.8%) | 121.27M +1.3M (+1.1%) | 2.92% -0.231 pp | 0.03% 0.000 pp | USD78.20 +55.6% | 19 qtrs — |
| 8 | GOLDMAN SACHS GROUP INC | 965.9K +262.4K (+37.3%) | 117.51M +38.6M (+48.9%) | 2.83% +0.757 pp | 0.01% +0.005 pp | USD111.83 +8.8% | 24 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 816.5K +2.9K (+0.4%) | 99.34M +8.0M (+8.8%) | 2.39% -0.006 pp | 0.01% +0.000 pp | USD45.65 +166.5% | 27 qtrs — |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 712.0K -26.1K (-3.5%) | 86.62M +3.8M (+4.6%) | 2.09% -0.089 pp | 0.59% -0.005 pp | USD69.09 +76.1% | 15 qtrs — |
| 11 | HOOD RIVER CAPITAL MANAGEMENT LLC | 690.4K +11.9K (+1.8%) | 83.98M +7.9M (+10.3%) | 2.02% +0.023 pp | 0.92% +0.022 pp | USD68.22 +78.3% | 7 qtrs — |
| 12 | INVESCO LTD. | 684.6K +298.8K (+77.4%) | 83.28M +40.0M (+92.4%) | 2.01% +0.869 pp | 0.01% +0.006 pp | USD97.72 +24.5% | 20 qtrs — |
| 13 | MORGAN STANLEY | 667.8K +119.9K (+21.9%) | 81.23M +19.8M (+32.2%) | 1.96% +0.342 pp | 0.00% +0.001 pp | USD88.76 +37.1% | 27 qtrs — |
| 14 | UBS GROUP AG | 659.3K -196.8K (-23.0%) | 80.20M -15.8M (-16.5%) | 1.93% -0.592 pp | 0.01% -0.002 pp | USD87.02 +39.8% | 27 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 570.0K +171.8K (+43.2%) | 69.34M +24.7M (+55.2%) | 1.67% +0.497 pp | 0.01% +0.003 pp | USD106.47 +14.3% | 17 qtrs — |
| 16 | EVENTIDE ASSET MANAGEMENT, LLC | 548.3K +971.0 (+0.2%) | 66.70M +5.3M (+8.6%) | 1.61% -0.007 pp | 1.04% +0.032 pp | USD60.77 +100.2% | 11 qtrs — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 489.7K +38.7K (+8.6%) | 59.57M +9.0M (+17.7%) | 1.44% +0.106 pp | 0.01% +0.002 pp | USD85.42 +42.4% | 6 qtrs — |
| 18 | TWO SIGMA INVESTMENTS, LP | 436.0K -199.4K (-31.4%) | 53.04M -18.3M (-25.6%) | 1.28% -0.596 pp | 0.07% -0.031 pp | USD123.86 -1.8% | 5 qtrs — |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 433.3K +217.2K (+100.5%) | 52.71M +28.5M (+117.4%) | 1.27% +0.633 pp | 0.01% +0.005 pp | USD117.93 +3.2% | 7 qtrs — |
| 20 | JPMORGAN CHASE & CO | 375.3K -17.1K (-4.4%) | 45.65M +1.6M (+3.7%) | 1.10% -0.057 pp | 0.00% +0.000 pp | USD90.53 +34.4% | 27 qtrs — |
| 21 | TWO SIGMA ADVISERS, LP | 362.3K -61.0K (-14.4%) | 44.07M -3.4M (-7.2%) | 1.06% -0.186 pp | 0.09% -0.009 pp | USD126.39 -3.8% | 3 qtrs — |
| 22 | EMERALD ADVISERS, LLC | 351.3K -36.2K (-9.3%) | 42.74M -745.8K (-1.7%) | 1.03% -0.113 pp | 1.32% -0.077 pp | USD55.93 +117.5% | 27 qtrs — |
| 23 | NORTHERN TRUST CORP | 339.2K -8.3K (-2.4%) | 41.27M +2.3M (+5.8%) | 0.99% -0.030 pp | 0.01% +0.000 pp | USD44.21 +175.2% | 27 qtrs — |
| 24 | WASATCH ADVISORS LP | 331.8K +6.6K (+2.0%) | 40.37M +3.9M (+10.6%) | 0.97% +0.014 pp | 0.24% +0.044 pp | USD69.43 +75.2% | 8 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 323.0K +2.2K (+0.7%) | 39.30M +3.3M (+9.2%) | 0.95% +0.001 pp | 0.01% +0.000 pp | USD44.03 +176.3% | 27 qtrs — |
| 26 | BAILLIE GIFFORD & CO | 316.5K +55.8K (+21.4%) | 38.50M +9.2M (+31.6%) | 0.93% +0.159 pp | 0.03% +0.010 pp | USD68.88 +76.6% | 20 qtrs — |
| 27 | BRAIDWELL LP | 315.3K -35.9K (-10.2%) | 38.36M -1.0M (-2.7%) | 0.92% -0.111 pp | 1.23% +0.058 pp | USD76.00 +60.1% | 13 qtrs — |
| 28 | FRONTIER CAPITAL MANAGEMENT CO LLC | 302.8K +83.3K (+38.0%) | 36.83M +12.2M (+49.6%) | 0.89% +0.240 pp | 0.39% +0.170 pp | USD102.71 +18.4% | 5 qtrs — |
| 29 | ZEVENBERGEN CAPITAL INVESTMENTS LLC | 280.2K +21.7K (+8.4%) | 34.08M +5.1M (+17.5%) | 0.82% +0.059 pp | 0.76% +0.194 pp | USD122.39 -0.6% | 3 qtrs — |
| 30 | BANK OF AMERICA CORP /DE/ | 279.3K +63.3K (+29.3%) | 33.98M +9.7M (+40.2%) | 0.82% +0.182 pp | 0.00% +0.001 pp | USD87.78 +38.6% | 27 qtrs — |
| 31 | WELLS FARGO & COMPANY/MN | 258.6K +33.8K (+15.0%) | 31.45M +6.2M (+24.7%) | 0.76% +0.095 pp | 0.01% +0.001 pp | USD85.32 +42.6% | 27 qtrs — |
| 32 | ROYCE & ASSOCIATES LP | 243.1K +— (+0.0%) | 29.58M +2.3M (+8.4%) | 0.71% -0.004 pp | 0.30% +0.028 pp | USD60.99 +99.5% | 17 qtrs — |
| 33 | EMERALD MUTUAL FUND ADVISERS TRUST | 229.9K -8.5K (-3.6%) | 27.97M +1.2M (+4.5%) | 0.67% -0.029 pp | 1.36% -0.019 pp | USD51.39 +136.7% | 27 qtrs — |
| 34 | CAPITAL WORLD INVESTORS | 227.4K +— (+0.0%) | 27.67M +2.1M (+8.4%) | 0.67% -0.004 pp | 0.00% +0.000 pp | USD67.28 +80.8% | 4 qtrs — |
| 35 | BANK OF NEW YORK MELLON CORP | 218.6K +6.8K (+3.2%) | 26.59M +2.8M (+11.9%) | 0.64% +0.016 pp | 0.00% +0.000 pp | USD59.25 +105.3% | 27 qtrs — |
| 36 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 217.1K -137.0K (-38.7%) | 26.41M -13.3M (-33.5%) | 0.64% -0.408 pp | 0.00% -0.002 pp | USD88.79 +37.0% | 21 qtrs — |
| 37 | LORD, ABBETT & CO. LLC | 216.9K +83.5K (+62.6%) | 26.38M +11.4M (+76.3%) | 0.64% +0.242 pp | 0.08% +0.036 pp | USD129.25 -5.9% | 3 qtrs — |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 209.5K -541.0 (-0.3%) | 25.49M +1.9M (+8.1%) | 0.61% -0.005 pp | 0.01% -0.001 pp | USD132.63 -8.3% | 27 qtrs — |
| 39 | BARCLAYS PLC | 199.7K +8.9K (+4.7%) | 24.29M -5.7M (-18.9%) | 0.59% +0.023 pp | 0.01% -0.002 pp | USD105.89 +14.9% | 27 qtrs — |
| 40 | PRINCIPAL FINANCIAL GROUP INC | 193.8K -48.3K (-19.9%) | 23.57M -3.6M (-13.2%) | 0.57% -0.146 pp | 0.01% -0.002 pp | USD140.94 -13.7% | 22 qtrs — |
| 41 | MARSHALL WACE, LLP | 190.5K -351.2K (-64.8%) | 23.17M -37.6M (-61.9%) | 0.56% -1.039 pp | 0.02% -0.041 pp | USD115.41 +5.4% | 4 qtrs — |
| 42 | ARROWMARK COLORADO HOLDINGS LLC | 187.0K -126.1K (-40.3%) | 22.75M -12.4M (-35.3%) | 0.55% -0.375 pp | 0.50% -0.152 pp | USD118.56 +2.6% | 14 qtrs — |
| 43 | DEUTSCHE BANK AG\ | 164.6K -8.1K (-4.7%) | 20.02M +652.0K (+3.4%) | 0.48% -0.027 pp | 0.01% +0.000 pp | USD88.71 +37.1% | 27 qtrs — |
| 44 | MILLENNIUM MANAGEMENT LLC | 149.0K +100.2K (+205.3%) | 18.13M +12.7M (+231.0%) | 0.44% +0.293 pp | 0.01% +0.005 pp | USD125.70 -3.2% | 15 qtrs — |
| 45 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 146.4K +— (+0.0%) | 17.81M +1.4M (+8.4%) | 0.43% -0.003 pp | 0.28% +0.039 pp | USD96.12 +26.6% | 4 qtrs — |
| 46 | BROWN CAPITAL MANAGEMENT LLC | 145.9K -167.9K (-53.5%) | 17.75M -17.5M (-49.6%) | 0.43% -0.498 pp | 1.46% +0.005 pp | USD67.28 +80.8% | 4 qtrs — |
| 47 | CITADEL ADVISORS LLC | 143.2K +18.3K (+14.7%) | 17.43M +3.4M (+24.3%) | 0.42% +0.052 pp | 0.00% +0.001 pp | USD72.59 +67.6% | 27 qtrs — |
| 48 | BLAIR WILLIAM & CO/IL | 135.9K +78.4K (+136.6%) | 16.53M +10.1M (+156.5%) | 0.40% +0.229 pp | 0.04% +0.027 pp | USD101.35 +20.0% | 10 qtrs — |
| 49 | AMERIPRISE FINANCIAL INC | 124.3K +9.5K (+8.3%) | 15.13M +2.2M (+17.4%) | 0.36% +0.026 pp | 0.00% +0.001 pp | USD111.16 +9.4% | 14 qtrs — |
| 50 | BANK OF MONTREAL /CAN/ | 124.2K +19.1K (+18.1%) | 15.11M +3.3M (+28.1%) | 0.36% +0.054 pp | 0.01% +0.001 pp | USD79.52 +53.0% | 11 qtrs — |
| 51 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 118.3K -14.7K (-11.1%) | 14.39M -533.6K (-3.6%) | 0.35% -0.045 pp | 0.05% -0.006 pp | USD124.81 -2.5% | 6 qtrs — |
| 52 | OPPENHEIMER & CO INC | 116.6K +4.9K (+4.4%) | 14.18M +1.7M (+13.2%) | 0.34% +0.013 pp | 0.20% +0.049 pp | USD101.85 +19.4% | 16 qtrs — |
| 53 | RAYMOND JAMES FINANCIAL INC | 112.5K -448.0 (-0.4%) | 13.71M +1.0M (+8.1%) | 0.33% -0.003 pp | 0.00% +0.000 pp | USD81.72 +48.9% | 5 qtrs — |
| 54 | SQUAREPOINT OPS LLC | 110.5K -22.0K (-16.6%) | 13.44M -1.4M (-9.6%) | 0.32% -0.067 pp | 0.01% -0.001 pp | USD114.33 +6.4% | 22 qtrs — |
| 55 | CANDRIAM S.C.A. | 109.2K +109.2K (+100.0%) | 13.28M +13.3M (+100.0%) | 0.32% +0.320 pp | 0.07% +0.066 pp | USD121.65 +0.0% | 1 qtrs NEW |
| 56 | STATE OF MICHIGAN RETIREMENT SYSTEM | 108.0K +— (+0.0%) | 13.14M +1.0M (+8.4%) | 0.32% -0.002 pp | 0.06% +0.006 pp | USD62.35 +95.1% | 5 qtrs — |
| 57 | LAGODA INVESTMENT MANAGEMENT, L.P. | 104.8K -3.3K (-3.0%) | 12.75M +624.6K (+5.2%) | 0.31% -0.011 pp | 7.38% +0.523 pp | USD71.82 +69.4% | 12 qtrs — |
| 58 | PANAGORA ASSET MANAGEMENT INC | 102.0K +25.7K (+33.7%) | 12.41M +3.9M (+45.0%) | 0.30% +0.074 pp | 0.04% +0.010 pp | USD114.58 +6.2% | 2 qtrs — |
| 59 | MONTANARO ASSET MANAGEMENT LTD | 101.9K -28.6K (-21.9%) | 12.40M -2.3M (-15.4%) | 0.30% -0.086 pp | 3.46% -0.203 pp | USD81.53 +49.2% | 19 qtrs — |
| 60 | NEXT CENTURY GROWTH INVESTORS LLC | 98.5K +44.1K (+81.2%) | 11.98M +5.9M (+96.4%) | 0.29% +0.128 pp | 0.83% +0.387 pp | USD128.47 -5.3% | 3 qtrs — |
| 61 | BELLEVUE GROUP AG | 97.9K -19.1K (-16.3%) | 11.91M -1.2M (-9.3%) | 0.29% -0.058 pp | 0.23% -0.047 pp | USD28.95 +320.2% | 23 qtrs — |
| 62 | PORTOLAN CAPITAL MANAGEMENT, LLC | 96.9K +28.0K (+40.6%) | 11.79M +4.1M (+52.5%) | 0.28% +0.081 pp | 0.63% +0.213 pp | USD114.93 +5.8% | 4 qtrs — |
| 63 | MAN GROUP PLC | 95.7K -17.9K (-15.8%) | 11.64M -1.1M (-8.7%) | 0.28% -0.054 pp | 0.02% -0.002 pp | USD116.93 +4.0% | 6 qtrs — |
| 64 | TREXQUANT INVESTMENT LP | 92.5K +12.1K (+15.0%) | 11.25M +2.2M (+24.7%) | 0.27% +0.034 pp | 0.10% +0.007 pp | USD132.40 -8.1% | 3 qtrs — |
| 65 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 92.4K +27.1K (+41.5%) | 11.25M +3.9M (+53.4%) | 0.27% +0.078 pp | 0.02% +0.006 pp | USD81.77 +48.8% | 5 qtrs — |
| 66 | SCHONFELD STRATEGIC ADVISORS LLC | 91.1K +64.7K (+245.8%) | 11.08M +8.1M (+274.9%) | 0.27% +0.189 pp | 0.05% +0.032 pp | USD118.92 +2.3% | 2 qtrs — |
| 67 | RHUMBLINE ADVISERS | 88.0K -5.3K (-5.7%) | 10.71M +236.6K (+2.3%) | 0.26% -0.017 pp | 0.01% +0.000 pp | USD72.41 +68.0% | 25 qtrs — |
| 68 | CREDIT AGRICOLE S A | 87.2K +23.6K (+37.1%) | 10.61M +3.5M (+48.7%) | 0.26% +0.068 pp | 0.02% +0.005 pp | USD114.76 +6.0% | 2 qtrs — |
| 69 | LEGAL & GENERAL GROUP PLC | 85.9K -2.3K (-2.6%) | 10.45M +554.3K (+5.6%) | 0.25% -0.008 pp | 0.00% +0.000 pp | USD118.23 +2.9% | 27 qtrs — |
| 70 | ENSIGN PEAK ADVISORS, INC | 80.6K +6.0K (+8.0%) | 9.81M +1.4M (+17.1%) | 0.24% +0.016 pp | 0.02% +0.004 pp | USD61.73 +97.1% | 17 qtrs — |
| 71 | RENAISSANCE GROUP LLC | 77.2K +1.2K (+1.5%) | 9.39M +859.0K (+10.1%) | 0.23% +0.002 pp | 0.38% +0.055 pp | USD112.34 +8.3% | 2 qtrs — |
| 72 | NUVEEN, LLC | 75.2K -1.2K (-1.6%) | 9.14M +575.3K (+6.7%) | 0.22% -0.005 pp | 0.00% +0.000 pp | USD67.28 +80.8% | 4 qtrs — |
| 73 | CITIGROUP INC | 72.0K -4.7K (-6.2%) | 8.76M +148.9K (+1.7%) | 0.21% -0.015 pp | 0.00% +0.000 pp | USD125.18 -2.8% | 27 qtrs — |
| 74 | JANUS HENDERSON GROUP PLC | 72.0K +52.5K (+270.5%) | 8.75M +6.6M (+301.8%) | 0.21% +0.154 pp | 0.00% +0.003 pp | USD108.15 +12.5% | 14 qtrs — |
| 75 | F/M INVESTMENTS LLC | 65.5K +8.6K (+15.2%) | 7.97M +1.6M (+24.9%) | 0.19% +0.024 pp | 0.30% +0.057 pp | USD142.76 -14.8% | 7 qtrs — |
| 76 | SWISS NATIONAL BANK | 63.9K +1.6K (+2.6%) | 7.77M +783.4K (+11.2%) | 0.19% +0.004 pp | 0.00% +0.001 pp | USD42.19 +188.3% | 19 qtrs — |
| 77 | ROYAL BANK OF CANADA | 62.8K -135.6K (-68.3%) | 7.64M -14.6M (-65.7%) | 0.18% -0.401 pp | 0.00% -0.002 pp | USD130.86 -7.0% | 27 qtrs — |
| 78 | PEREGRINE CAPITAL MANAGEMENT LLC | 60.2K -8.2K (-12.1%) | 7.32M -357.1K (-4.7%) | 0.18% -0.025 pp | 0.22% -0.007 pp | USD60.51 +101.0% | 14 qtrs — |
| 79 | BASTION ASSET MANAGEMENT INC. | 57.6K +12.7K (+28.3%) | 7.23M +2.1M (+40.8%) | 0.17% +0.037 pp | 3.99% +1.036 pp | USD114.29 +6.4% | 5 qtrs — |
| 80 | BIONDO INVESTMENT ADVISORS, LLC | 57.2K -1.2K (-2.0%) | 6.96M +410.5K (+6.3%) | 0.17% -0.004 pp | 0.84% +0.021 pp | USD143.72 -15.4% | 7 qtrs — |
| 81 | PRUDENTIAL FINANCIAL INC | 57.1K +10.8K (+23.4%) | 6.95M +1.8M (+33.8%) | 0.17% +0.031 pp | 0.01% +0.002 pp | USD90.98 +33.7% | 12 qtrs — |
| 82 | LISANTI CAPITAL GROWTH, LLC | 56.8K -150.0 (-0.3%) | 6.90M +519.5K (+8.1%) | 0.17% -0.001 pp | 1.64% +0.074 pp | USD91.81 +32.5% | 15 qtrs — |
| 83 | JANE STREET GROUP, LLC | 56.6K -75.2K (-57.1%) | 6.89M -7.9M (-53.4%) | 0.17% -0.223 pp | 0.00% -0.001 pp | USD101.92 +19.4% | 6 qtrs — |
| 84 | SEI INVESTMENTS CO | 55.3K +11.6K (+26.5%) | 6.73M +1.8M (+37.1%) | 0.16% +0.033 pp | 0.01% +0.001 pp | USD82.60 +47.3% | 16 qtrs — |
| 85 | LAZARD ASSET MANAGEMENT LLC | 51.4K -19.1K (-27.1%) | 6.25M -1.7M (-21.0%) | 0.15% -0.057 pp | 0.01% 0.000 pp | USD99.02 +22.9% | 12 qtrs — |
| 86 | FEDERATED HERMES, INC. | 47.3K +41.3K (+689.3%) | 5.75M +5.1M (+755.7%) | 0.14% +0.121 pp | 0.01% +0.008 pp | USD120.45 +1.0% | 2 qtrs — |
| 87 | PARKMAN HEALTHCARE PARTNERS LLC | 45.2K +45.2K (+100.0%) | 5.50M +5.5M (+100.0%) | 0.13% +0.132 pp | 0.52% +0.523 pp | USD121.65 +0.0% | 1 qtrs NEW |
| 88 | CANADA PENSION PLAN INVESTMENT BOARD | 44.6K +42.9K (+2,523.5%) | 5.43M +5.2M (+2,744.5%) | 0.13% +0.126 pp | 0.00% +0.004 pp | USD119.65 +1.7% | 7 qtrs — |
| 89 | ENVESTNET ASSET MANAGEMENT INC | 43.2K -3.9K (-8.2%) | 5.25M -25.1K (-0.5%) | 0.13% -0.012 pp | 0.00% +0.000 pp | USD93.16 +30.6% | 25 qtrs — |
| 90 | ALLIANCEBERNSTEIN L.P. | 42.1K +1.4K (+3.3%) | 5.13M +550.0K (+12.0%) | 0.12% +0.003 pp | 0.00% +0.000 pp | USD66.18 +83.8% | 26 qtrs — |
| 91 | GOTHAM ASSET MANAGEMENT, LLC | 40.9K +32.6K (+396.2%) | 4.97M +4.0M (+438.0%) | 0.12% +0.096 pp | 0.02% +0.014 pp | USD121.43 +0.2% | 3 qtrs — |
| 92 | MERIDIEM CAPITAL PARTNERS LP | 36.7K +36.7K (+100.0%) | 4.46M +4.5M (+100.0%) | 0.11% +0.108 pp | 0.27% +0.269 pp | USD121.65 +0.0% | 1 qtrs NEW |
| 93 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 32.9K -5.5K (-14.3%) | 4.04M -271.9K (-6.3%) | 0.10% -0.017 pp | 0.00% 0.000 pp | USD65.09 +86.9% | 6 qtrs — |
| 94 | BESSEMER GROUP INC | 33.0K +32.8K (+13,484.0%) | 4.02M +4.0M (+14,774.1%) | 0.10% +0.096 pp | 0.01% +0.006 pp | USD121.46 +0.2% | 6 qtrs — |
| 95 | NORDEA INVESTMENT MANAGEMENT AB | 32.0K -4.4K (-12.0%) | 3.95M -116.8K (-2.9%) | 0.09% -0.014 pp | 0.00% 0.000 pp | USD112.20 +8.4% | 2 qtrs — |
| 96 | STATE OF WISCONSIN INVESTMENT BOARD | 32.0K +28.9K (+940.7%) | 3.89M +3.5M (+1,028.4%) | 0.09% +0.085 pp | 0.01% +0.008 pp | USD118.87 +2.3% | 17 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 148 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Moonvest ETF MNVT | 4.83% | 2.51M | 0.75% |
| 2 | F/M Emerald Life Sciences Innovation ETF LFSC | 2.42% | 1.80M | 0.54% |
| 3 | Global X HealthTech ETF HEAL | 2.39% | 716.1K | 0.50% |
| 4 | YieldMax Ultra Option Income Strategy ETF ULTY | 2.06% | 17.82M | 1.40% |
| 5 | F/m Emerald Special Situations ETF SPIT | 1.87% | 541.1K | 0.89% |
| 6 | State Street SPDR S&P Health Care Equipment ETF XHE | 1.50% | 2.27M | 0.35% |
| 7 | Congress SMID Growth ETF CSMD | 1.43% | 6.77M | 0.68% |
| 8 | Invesco S&P SmallCap Health Care ETF PSCH | 1.07% | 1.76M | 0.29% |
| 9 | Invesco S&P SmallCap Momentum ETF XSMO | 0.73% | 22.16M | 0.36% |
| 10 | Invesco S&P SmallCap 600 Revenue ETF RZG | 0.63% | 907.1K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
1.45
Neutral
Buys
5
Sells
10
Shares acquired
38.6K
Shares disposed
26.7K
Cash buys
—
Cash sales
6.00
Net activity
+11,951
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Forsyth Matthew S. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-04 | Weill David | Director | M-Exempt | A | Common Stock | 3,571 | 14.20 | 50.7K | 15,705 | D | ↗ |
| 2026-03-04 | Lovell Stephanie | Director | S-Sale | D | Common Stock | 1,193 | 149.62 | 178.5K | 2,866 | D | ↗ |
| 2026-03-04 | Hernandez Gerardo | Officer | M-Exempt | A | Common Stock | 5,912 | 69.84 | 412.9K | 20,601 | D | ↗ |
| 2026-03-02 | Ranganath Anil P. | Officer | S-Sale | D | Common Stock | 864 | 139.12 | 120.2K | 13,091 | D | ↗ |
| 2026-03-02 | Hernandez Gerardo | Officer | S-Sale | D | Common Stock | 375 | 139.12 | 52.2K | 14,689 | D | ↗ |
| 2026-03-02 | Corcoran Nicholas | Officer | S-Sale | D | Common Stock | 2,966 | 139.12 | 412.6K | 29,831 | D | ↗ |
| 2026-02-18 | Cecere Giovanni | Officer | A-Award | A | Common Stock | 11,082 | 0.00 | — | 19,057 | D | ↗ |
| 2026-02-02 | Cecere Giovanni | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-23 | Corcoran Nicholas | Officer | F-InKind | D | Common Stock | 984 | 135.30 | 133.1K | 32,797 | D | ↗ |
| 2025-12-04 | Hernandez Gerardo | Officer | S-Sale | D | Common Stock | 920 | 139.62 | 128.5K | 15,064 | D | ↗ |
| 2025-12-03 | Weill David | Director | S-Sale | D | Common Stock | 5,000 | 138.64 | 693.2K | 12,134 | D | ↗ |
| 2025-11-25 | Ranganath Anil P. | Officer | M-Exempt | A | Common Stock | 3,000 | 93.88 | 281.6K | 16,955 | D | ↗ |
| 2025-11-17 | Hassanein Waleed H | Director / Officer | P-Purchase | A | Common Stock | 8,775 | 114.00 | 1.00M | 495,009 | I | ↗ |
| 2025-10-29 | Basile Edward M | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,142 | 0.70 | 2.9K | 0 | D | ↗ |
| 2025-08-07 | Hassanein Waleed H | Director / Officer | P-Purchase | A | Common Stock | 1,858 | 116.85 | 217.1K | 486,234 | I | ↗ |
| 2025-08-06 | Hassanein Waleed H | Director / Officer | P-Purchase | A | Common Stock | 8,400 | 118.68 | 996.9K | 477,759 | I | ↗ |
| 2025-08-04 | Basile Edward M | Director | M-Exempt | A | Common Stock | 4,143 | 0.70 | 2.9K | 7,009 | D | ↗ |
| 2025-06-09 | Ranganath Anil P. | Officer | S-Sale | D | Common Stock | 686 | 139.80 | 95.9K | 13,955 | D | ↗ |
| 2025-05-27 | Basile Edward M | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 0.70 | 3.5K | 8,285 | D | ↗ |
| 2025-05-23 | Weill David | Director | S-Sale | D | Common Stock | 732 | 123.88 | 90.7K | 12,134 | D | ↗ |
| 2025-05-22 | Weill David | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 12,866 | D | ↗ |
| 2025-05-22 | TOBIN JAMES R | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 4,059 | D | ↗ |
| 2025-05-22 | RAINES MERILEE | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 4,059 | D | ↗ |
| 2025-05-22 | Lovell Stephanie | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 4,059 | D | ↗ |
| 2025-05-22 | KANIA EDWIN M JR | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 260,810 | D | ↗ |
| 2025-05-22 | Gunderson Thomas James | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 4,059 | D | ↗ |
| 2025-05-22 | Basile Edward M | Director | A-Award | A | Common Stock | 2,134 | 0.00 | — | 2,866 | D | ↗ |
| 2025-05-09 | Basile Edward M | Director | M-Exempt | D | Stock Option (Right to Buy) | 6,000 | 0.70 | 4.2K | 13,285 | D | ↗ |
| 2025-03-14 | Cecere Giovanni | Officer | — | — | Common Stock | 0 | 0.00 | — | 7,975 | D | ↗ |
| 2025-03-03 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 2,407 | 76.43 | 184.0K | 36,042 | D | ↗ |
| 2025-02-25 | Hassanein Waleed H | Director / Officer | A-Award | A | Common Stock | 59,781 | 0.00 | — | 121,424 | D | ↗ |
| 2025-02-24 | Ranganath Anil P. | Officer | A-Award | A | Common Stock | 5,634 | 0.00 | — | 14,641 | D | ↗ |
| 2025-02-24 | Khayal Tamer I | Officer | A-Award | A | Stock Option (Right to Buy) | 26,499 | 77.12 | 2.04M | 26,499 | D | ↗ |
| 2025-02-24 | Hernandez Gerardo | Officer | A-Award | A | Stock Option (Right to Buy) | 5,299 | 77.12 | 408.7K | 5,299 | D | ↗ |
| 2025-02-24 | Corcoran Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 19,079 | 77.12 | 1.47M | 19,079 | D | ↗ |
| 2025-01-07 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 1,083 | 13.28 | 14.4K | 21,926 | D | ↗ |
| 2024-12-09 | Hernandez Gerardo | Officer | A-Award | A | Stock Option (Right to Buy) | 18,922 | 69.84 | 1.32M | 18,922 | D | ↗ |
| 2024-12-02 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,084 | 13.28 | 14.4K | 16,250 | D | ↗ |
| 2024-12-02 | Hernandez Gerardo | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-11 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 1,458 | 38.46 | 56.1K | 22,301 | D | ↗ |
| 2024-11-05 | Basile Edward M | Director | M-Exempt | A | Common Stock | 6,750 | 28.12 | 189.8K | 7,482 | D | ↗ |
| 2024-11-01 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 1,083 | 13.28 | 14.4K | 21,926 | D | ↗ |
| 2024-10-15 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 3,518 | 132.82 | 467.3K | 63,143 | D | ↗ |
| 2024-10-01 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 318 | 150.38 | 47.8K | 21,157 | D | ↗ |
| 2024-09-16 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 1,865 | 152.30 | 284.0K | 67,495 | — | ↗ |
| 2024-09-13 | TOBIN JAMES R | Director | G-Gift | D | Common Stock | 18,000 | 0.00 | — | 155,146 | — | ↗ |
| 2024-09-03 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 396 | 160.67 | 63.6K | 21,755 | — | ↗ |
| 2024-08-27 | Corcoran Nicholas | Officer | M-Exempt | A | Common Stock | 2,190 | 83.14 | 182.1K | 31,105 | — | ↗ |
| 2024-08-22 | Hassanein Waleed H | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 16.14 | 403.5K | 153,000 | — | ↗ |
| 2024-08-21 | Hassanein Waleed H | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 16.00 | 320.0K | 265,714 | — | ↗ |
| 2024-08-15 | Hassanein Waleed H | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,625 | 13.28 | 114.5K | 113,500 | — | ↗ |
| 2024-08-08 | TOBIN JAMES R | Director | S-Sale | D | Common Stock | 7,336 | 159.96 | 1.17M | 173,146 | — | ↗ |
| 2024-08-07 | Ranganath Anil P. | Officer | S-Sale | D | Common Stock | 4,289 | 152.20 | 652.8K | 8,893 | — | ↗ |
| 2024-08-06 | Basile Edward M | Director | S-Sale | D | Common Stock | 1,830 | 148.26 | 271.3K | 5,652 | — | ↗ |
| 2024-08-01 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,458 | 38.46 | 56.1K | 10,209 | — | ↗ |
| 2024-07-15 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 1,397 | 143.61 | 200.6K | 68,871 | — | ↗ |
| 2024-07-01 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 1,458 | 38.46 | 56.1K | 22,301 | — | ↗ |
| 2024-06-14 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 100 | 144.52 | 14.5K | 61,643 | — | ↗ |
| 2024-06-05 | Ranganath Anil P. | Officer | S-Sale | D | Common Stock | 703 | 135.21 | 95.1K | 8,809 | — | ↗ |
| 2024-06-05 | Basile Edward M | Director | S-Sale | D | Common Stock | 1,193 | 138.08 | 164.7K | 732 | — | ↗ |
| 2024-06-03 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 567 | 133.67 | 75.8K | 21,452 | — | ↗ |
| 2024-06-03 | Gordon Stephen | Officer | M-Exempt | A | Common Stock | 2,060 | 38.46 | 79.2K | 23,359 | — | ↗ |
| 2024-05-29 | Weill David | Director | S-Sale | D | Common Stock | 1,193 | 141.65 | 169.0K | 10,732 | — | ↗ |
| 2024-05-29 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 2,000 | 141.27 | 282.5K | 21,299 | — | ↗ |
| 2024-05-23 | Weill David | Director | A-Award | A | Stock Option (Right to Buy) | 1,154 | 137.53 | 158.7K | 1,154 | — | ↗ |
| 2024-05-23 | TOBIN JAMES R | Director | A-Award | A | Stock Option (Right to Buy) | 1,154 | 137.53 | 158.7K | 1,154 | — | ↗ |
| 2024-05-23 | RAINES MERILEE | Director | A-Award | A | Stock Option (Right to Buy) | 1,154 | 137.53 | 158.7K | 1,154 | — | ↗ |
| 2024-05-23 | Lovell Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 1,154 | 137.53 | 158.7K | 1,154 | — | ↗ |
| 2024-05-23 | KANIA EDWIN M JR | Director | A-Award | A | Stock Option (Right to Buy) | 1,154 | 137.53 | 158.7K | 1,154 | — | ↗ |
| 2024-05-23 | Gunderson Thomas James | Director | A-Award | A | Common Stock | 732 | 0.00 | — | 1,925 | — | ↗ |
| 2024-05-23 | Basile Edward M | Director | A-Award | A | Stock Option (Right to Buy) | 1,154 | 137.53 | 158.7K | 1,154 | — | ↗ |
| 2024-05-15 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 744 | 136.26 | 101.4K | 61,643 | — | ↗ |
| 2024-05-10 | Weill David | Director | S-Sale | D | Common Stock | 2,500 | 129.82 | 324.6K | 11,193 | — | ↗ |
| 2024-05-07 | Basile Edward M | Director | S-Sale | D | Common Stock | 2,130 | 128.43 | 273.6K | 6,220 | — | ↗ |
| 2024-05-06 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,839 | 66.10 | 386.0K | 14,183 | — | ↗ |
| 2024-05-06 | Hassanein Waleed H | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 30,000 | 13.28 | 398.4K | 148,000 | — | ↗ |
| 2024-05-06 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 128.00 | 1.92M | 23,299 | — | ↗ |
| 2024-05-06 | Corcoran Nicholas | Officer | S-Sale | D | Common Stock | 3,222 | 129.91 | 418.6K | 21,105 | — | ↗ |
| 2024-05-03 | TOBIN JAMES R | Director | S-Sale | D | Common Stock | 5,130 | 124.76 | 640.0K | 200,041 | — | ↗ |
| 2024-05-02 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 82 | 122.67 | 10.1K | 61,643 | — | ↗ |
| 2024-05-01 | TOBIN JAMES R | Director | S-Sale | D | Common Stock | 1,704 | 106.89 | 182.1K | 207,271 | — | ↗ |
| 2024-05-01 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 15,892 | 109.83 | 1.75M | 15,175 | — | ↗ |
| 2024-05-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 22,500 | 120.25 | 2.71M | 74,087 | — | ↗ |
| 2024-04-17 | Hassanein Waleed H | Director / Officer | M-Exempt | A | Common Stock | 4,000 | 13.28 | 53.1K | 78,087 | — | ↗ |
| 2024-04-10 | Hassanein Waleed H | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 13.28 | 159.4K | 238,000 | — | ↗ |
| 2024-04-09 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 4,980 | 91.11 | 453.7K | 25,185 | — | ↗ |
| 2024-04-08 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,388 | 16.14 | 70.8K | 8,341 | — | ↗ |
| 2024-04-04 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 2,917 | 16.14 | 47.1K | 30,132 | — | ↗ |
| 2024-04-03 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 5,053 | 13.28 | 67.1K | 30,238 | — | ↗ |
| 2024-04-01 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 15,000 | 74.01 | 1.11M | 23,299 | — | ↗ |
| 2024-03-08 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 1,317 | 87.63 | 115.4K | 25,185 | — | ↗ |
| 2024-03-08 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 1,903 | 87.63 | 166.8K | 23,299 | — | ↗ |
| 2024-03-04 | Gordon Stephen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 38.46 | 576.9K | 52,477 | — | ↗ |
| 2024-03-01 | TOBIN JAMES R | Director | S-Sale | D | Common Stock | 2,900 | 84.74 | 245.7K | 220,511 | — | ↗ |
| 2024-03-01 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 10,000 | 13.28 | 132.8K | 36,502 | — | ↗ |
| 2024-02-23 | Khayal Tamer I | Officer | A-Award | A | Stock Option (Right to Buy) | 18,690 | 83.14 | 1.55M | 18,690 | — | ↗ |
| 2024-02-23 | Hassanein Waleed H | Director / Officer | A-Award | A | Common Stock | 36,755 | 0.00 | — | 543,446 | — | ↗ |
| 2024-02-23 | Gordon Stephen | Officer | A-Award | A | Common Stock | 12,127 | 0.00 | — | 25,202 | — | ↗ |
| 2024-02-23 | Corcoran Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 17,632 | 83.14 | 1.47M | 17,632 | — | ↗ |
| 2024-02-20 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 250 | 90.00 | 22.5K | 14,375 | — | ↗ |
| 2024-02-16 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 1,714 | 16.14 | 27.7K | 17,233 | — | ↗ |
| 2024-02-15 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 776 | 16.00 | 12.4K | 1,144 | — | ↗ |
| 2024-02-14 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 3,050 | 16.00 | 48.8K | 17,425 | — | ↗ |
| 2024-02-07 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 736 | 90.09 | 66.3K | 14,375 | — | ↗ |
| 2024-02-06 | Basile Edward M | Director | S-Sale | D | Common Stock | 5,773 | 86.27 | 498.0K | 9,734 | — | ↗ |
| 2024-02-01 | Gordon Stephen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,523 | 38.46 | 97.0K | 67,477 | — | ↗ |
| 2024-01-23 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 2,330 | 16.00 | 37.3K | 16,705 | — | ↗ |
| 2024-01-16 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 133 | 81.06 | 10.8K | 14,375 | — | ↗ |
| 2024-01-02 | Gordon Stephen | Officer | M-Exempt | A | Common Stock | 15,000 | 13.28 | 199.2K | 28,075 | — | ↗ |
| 2023-12-15 | Provost Miriam | Officer | G-Gift | D | Common Stock | 1,785 | 0.00 | — | 23,348 | — | ↗ |
| 2023-12-13 | Provost Miriam | Officer | M-Exempt | D | Stock Option (Right to Buy) | 415 | 16.14 | 6.7K | 7,811 | — | ↗ |
| 2023-12-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 2,925 | 74.06 | 216.6K | 511,266 | — | ↗ |
| 2023-11-28 | TOBIN JAMES R | Director | S-Sale | D | Common Stock | 10,000 | 70.14 | 701.4K | 233,591 | — | ↗ |
| 2023-11-17 | Gordon Stephen | Officer | G-Gift | D | Common Stock | 5,714 | 0.00 | — | 13,075 | — | ↗ |
| 2023-11-07 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 15,000 | 64.32 | 964.8K | 514,191 | — | ↗ |
| 2023-10-02 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 5,000 | 54.22 | 271.1K | 18,789 | — | ↗ |
| 2023-09-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 63 | 65.63 | 4.1K | 536,628 | — | ↗ |
| 2023-08-31 | Provost Miriam | Officer | M-Exempt | A | Common Stock | 3,695 | 38.46 | 142.1K | 26,319 | — | ↗ |
| 2023-08-29 | Weill David | Director | P-Purchase | A | Common Stock | 2,500 | 62.00 | 155.0K | 13,693 | — | ↗ |
| 2023-08-01 | Ranganath Anil P. | Officer | A-Award | A | Common Stock | 9,512 | 0.00 | — | 9,512 | — | ↗ |
| 2023-08-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 727 | 91.91 | 66.8K | 543,464 | — | ↗ |
| 2023-07-18 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 3,539 | 16.14 | 57.1K | 17,914 | — | ↗ |
| 2023-07-13 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,974 | 16.14 | 48.0K | 21,249 | — | ↗ |
| 2023-07-03 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 4,653 | 82.74 | 385.0K | 544,781 | — | ↗ |
| 2023-06-05 | Ranganath Anil P. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 5,546 | 71.44 | 396.2K | 553,645 | — | ↗ |
| 2023-05-25 | Weill David | Director | A-Award | A | Stock Option (Right to Buy) | 1,916 | 71.33 | 136.7K | 1,916 | — | ↗ |
| 2023-05-25 | TOBIN JAMES R | Director | A-Award | A | Common Stock | 1,193 | 0.00 | — | 1,193 | — | ↗ |
| 2023-05-25 | RAINES MERILEE | Director | A-Award | A | Common Stock | 1,193 | 0.00 | — | 1,193 | — | ↗ |
| 2023-05-25 | Lovell Stephanie | Director | A-Award | A | Common Stock | 1,193 | 0.00 | — | 1,193 | — | ↗ |
| 2023-05-25 | KANIA EDWIN M JR | Director | A-Award | A | Stock Option (Right to Buy) | 1,916 | 71.33 | 136.7K | 1,916 | — | ↗ |
| 2023-05-25 | Gunderson Thomas James | Director | A-Award | A | Common Stock | 1,193 | 0.00 | — | 1,193 | — | ↗ |
| 2023-05-25 | Basile Edward M | Director | A-Award | A | Stock Option (Right to Buy) | 1,916 | 71.33 | 136.7K | 1,916 | — | ↗ |
| 2023-05-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 5,406 | 77.84 | 420.8K | 561,285 | — | ↗ |
| 2023-05-01 | Gordon Stephen | Officer | M-Exempt | A | Common Stock | 5,000 | 16.14 | 80.7K | 23,789 | — | ↗ |
| 2023-04-21 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 8,700 | 85.44 | 743.3K | 17,701 | — | ↗ |
| 2023-04-03 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 3,359 | 74.34 | 249.7K | 570,832 | — | ↗ |
| 2023-03-10 | Hassanein Waleed H | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 193,074 | 2.21 | 426.7K | 1 | — | ↗ |
| 2023-03-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 2,600 | 80.17 | 208.4K | 386,017 | — | ↗ |
| 2023-03-01 | Gordon Stephen | Officer | M-Exempt | A | Common Stock | 5,000 | 16.14 | 80.7K | 23,789 | — | ↗ |
| 2023-03-01 | Basile Edward M | Director | S-Sale | D | Common Stock | 3,500 | 80.10 | 280.4K | 14,314 | — | ↗ |
| 2023-02-28 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 10,000 | 80.15 | 801.5K | 14,375 | — | ↗ |
| 2023-02-28 | KANIA EDWIN M JR | Director | J-Other | A | Common Stock | 145,601 | 79.76 | 11.61M | 159,875 | — | ↗ |
| 2023-02-27 | Weill David | Director | M-Exempt | A | Common Stock | 5,934 | 14.20 | 84.3K | 15,934 | — | ↗ |
| 2023-02-27 | Basile Edward M | Director | S-Sale | D | Common Stock | 1,500 | 76.20 | 114.3K | 21,314 | — | ↗ |
| 2023-02-23 | TOBIN JAMES R | Director | S-Sale | D | Common Stock | 10,000 | 75.13 | 751.3K | 243,591 | — | ↗ |
| 2023-02-23 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 6,218 | 72.02 | 447.8K | 36,005 | — | ↗ |
| 2023-02-23 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 20,000 | 75.15 | 1.50M | 388,617 | — | ↗ |
| 2023-02-20 | Provost Miriam | Officer | A-Award | A | Stock Option (Right to Buy) | 8,705 | 66.10 | 575.4K | 8,705 | — | ↗ |
| 2023-02-20 | Khayal Tamer I | Officer | A-Award | A | Stock Option (Right to Buy) | 20,022 | 66.10 | 1.32M | 20,022 | — | ↗ |
| 2023-02-20 | Hassanein Waleed H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 57,165 | 66.10 | 3.78M | 57,165 | — | ↗ |
| 2023-02-20 | Gordon Stephen | Officer | A-Award | A | Stock Option (Right to Buy) | 20,022 | 66.10 | 1.32M | 20,022 | — | ↗ |
| 2023-02-20 | DAMME LAURA | Officer | A-Award | A | Common Stock | 5,685 | 0.00 | — | 5,685 | — | ↗ |
| 2023-02-20 | Corcoran Nicholas | Officer | A-Award | A | Common Stock | 12,886 | 0.00 | — | 12,886 | — | ↗ |
| 2023-02-14 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,070 | 16.00 | 65.1K | 40,215 | — | ↗ |
| 2023-02-14 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 2,173 | 70.08 | 152.3K | 389,112 | — | ↗ |
| 2023-02-01 | Hassanein Waleed H | Director / Officer | S-Sale | D | Common Stock | 7,500 | 64.21 | 481.6K | 391,285 | — | ↗ |
| 2023-02-01 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 5,000 | 62.64 | 313.2K | 5,714 | — | ↗ |
| 2023-02-01 | Carey John F | Officer | S-Sale | D | Common Stock | 214 | 65.81 | 14.1K | 14,120 | — | ↗ |
| 2023-01-23 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 3,142 | 65.07 | 204.4K | 1,300 | — | ↗ |
| 2023-01-23 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 900 | 66.12 | 59.5K | 398,785 | — | ↗ |
| 2023-01-23 | Corcoran Nicholas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-20 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,558 | 0.00 | — | 47,427 | — | ↗ |
| 2023-01-20 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 6,332 | 65.19 | 412.8K | 411,147 | — | ↗ |
| 2023-01-18 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,300 | 0.00 | — | 52,985 | — | ↗ |
| 2023-01-18 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 1,306 | 65.09 | 85.0K | 417,479 | — | ↗ |
| 2023-01-17 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 7,500 | 64.14 | 481.1K | 418,785 | — | ↗ |
| 2023-01-17 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 5,000 | 60.12 | 300.6K | 5,714 | — | ↗ |
| 2023-01-17 | Carey John F | Officer | S-Sale | D | Common Stock | 446 | 61.77 | 27.5K | 15,021 | — | ↗ |
| 2023-01-13 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 5,900 | 16.00 | 94.4K | 7,200 | — | ↗ |
| 2023-01-03 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 4,100 | 16.00 | 65.6K | 5,400 | — | ↗ |
| 2022-12-15 | DAMME LAURA | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,740 | 0.00 | — | 14,063 | — | ↗ |
| 2022-12-14 | DAMME LAURA | Officer | M-Exempt | A | Common Stock | 5,947 | 38.46 | 228.7K | 5,947 | — | ↗ |
| 2022-12-13 | Provost Miriam | Officer | M-Exempt | A | Common Stock | 5,918 | 38.46 | 227.6K | 19,469 | — | ↗ |
| 2022-12-09 | Provost Miriam | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,977 | 0.00 | — | 21,023 | — | ↗ |
| 2022-12-05 | Carey John F | Officer | M-Exempt | A | Common Stock | 36 | 0.28 | 10.08 | 13,844 | — | ↗ |
| 2022-12-02 | Carey John F | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,237 | 0.00 | — | 36 | — | ↗ |
| 2022-12-01 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,051 | 0.00 | — | 0 | — | ↗ |
| 2022-12-01 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 31 | 62.15 | 1.9K | 5,714 | — | ↗ |
| 2022-12-01 | Carey John F | Officer | S-Sale | D | Common Stock | 100 | 62.45 | 6.2K | 771 | — | ↗ |
| 2022-11-23 | Lovell Stephanie | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,657 | 0.00 | — | 8,543 | — | ↗ |
| 2022-11-22 | Lovell Stephanie | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,800 | 0.00 | — | 14,200 | — | ↗ |
| 2022-11-15 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,254 | 0.00 | — | 11,051 | — | ↗ |
| 2022-11-15 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 14,483 | 60.13 | 870.9K | 426,285 | — | ↗ |
| 2022-11-11 | Khayal Tamer I | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,702 | 0.00 | — | 15,305 | — | ↗ |
| 2022-11-11 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 2,748 | 60.03 | 165.0K | 440,768 | — | ↗ |
| 2022-11-10 | Weill David | Director | M-Exempt | A | Common Stock | 21,645 | 16.00 | 346.3K | 35,145 | — | ↗ |
| 2022-11-07 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 3,044 | 60.04 | 182.8K | 1,300 | — | ↗ |
| 2022-11-07 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 2,769 | 60.07 | 166.3K | 443,516 | — | ↗ |
| 2022-11-07 | Gordon Stephen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,272 | 0.00 | — | 40,728 | — | ↗ |
| 2022-11-01 | Carey John F | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 0.00 | — | 9,273 | — | ↗ |
| 2022-10-03 | Gordon Stephen | Officer | M-Exempt | A | Common Stock | 10,000 | 2.21 | 22.1K | 15,714 | — | ↗ |
| 2022-10-03 | Carey John F | Officer | S-Sale | D | Common Stock | 680 | 42.63 | 29.0K | 771 | — | ↗ |
| 2022-09-07 | Hassanein Waleed H | Officer | S-Sale | D | Common Stock | 2,277 | 55.00 | 125.2K | 464,008 | — | ↗ |
| 2022-09-02 | Provost Miriam | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,600 | 0.00 | — | 18,281 | — | ↗ |
| 2022-09-01 | Gordon Stephen | Officer | S-Sale | D | Common Stock | 10,000 | 50.93 | 509.3K | 5,714 | — | ↗ |
| 2022-09-01 | Carey John F | Officer | S-Sale | D | Common Stock | 1,699 | 51.38 | 87.3K | 771 | — | ↗ |
| 2022-08-24 | Khayal Tamer I | Officer | S-Sale | D | Common Stock | 2,514 | 50.18 | 126.2K | 24,776 | — | ↗ |
| 2022-08-23 | Khayal Tamer I | Officer | M-Exempt | A | Common Stock | 8,024 | 2.21 | 17.7K | 9,324 | — | ↗ |
Executive team
Top executives
EBIT / Employee
166.6K
Shares Outstanding
34.54M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Waleed H. Hassanein, M.D. President and Chief Executive Officer | 776.9K | — | 4.36M | 4.36M | 1.40M | 14.5K | 10.92M | 79.92% | ↗ |
| 2 | 2025 | Tamer Khayal, M.D. Former Chief Commercial Officer | 496.3K | — | 1.36M | 1.36M | 525.8K | 14.5K | 3.75M | 72.36% | ↗ |
| 3 | 2025 | Nicholas Corcoran Senior Vice President of Supply Chain and Operations | 451.7K | — | 977.6K | 976.2K | 399.7K | 14.5K | 2.82M | 69.29% | ↗ |
| 4 | 2025 | Gerardo Hernandez Chief Financial Officer | 488.5K | — | 271.5K | 271.1K | 525.0K | 14.5K | 1.57M | 34.55% | ↗ |
| 5 | 2025 | Anil Ranganath Former Senior Vice President, General Counsel and Corporate Secretary | 412.3K | — | 434.5K | 433.8K | 208.0K | 14.5K | 1.50M | 57.77% | ↗ |
| 6 | 2024 | Waleed H. Hassanein, M.D. President and Chief Executive Officer | 688.5K | — | 3.06M | 3.04M | 1.40M | 14.3K | 8.20M | 74.35% | ↗ |
| 7 | 2024 | Stephen Gordon Former Chief Financial Officer | 470.8K | — | 1.83M | 2.79M | 572.4K | 1.10M | 6.76M | 68.27% | ↗ |
| 8 | 2024 | Tamer Khayal, M.D. Chief Commercial Officer | 474.2K | — | 1.01M | 1.00M | 577.8K | 14.3K | 3.08M | 65.36% | ↗ |
| 9 | 2024 | Tamer Khayal, M.D. Former Chief Commercial Officer | 474.2K | — | 1.01M | 1.00M | 577.8K | 14.3K | 3.08M | 65.36% | ↗ |
| 10 | 2024 | Nicholas Corcoran Senior Vice President of Supply Chain and Operations | 421.2K | — | 951.2K | 946.5K | 391.5K | 14.3K | 2.72M | 69.65% | ↗ |
| 11 | 2024 | Gerardo Hernandez Chief Financial Officer | 17.3K | — | 870.4K | 869.7K | — | — | 1.76M | 99.02% | ↗ |
| 12 | 2024 | Anil Ranganath Senior Vice President, General Counsel and Corporate Secretary | 400.0K | — | — | — | 180.0K | 14.3K | 594.3K | 0.00% | ↗ |
| 13 | 2024 | Anil Ranganath Former Senior Vice President, General Counsel and Corporate Secretary | 400.0K | — | — | — | 180.0K | 14.3K | 594.3K | 0.00% | ↗ |
| 14 | 2023 | Waleed Hassanein, M.D. President and Chief Executive Officer | 633.8K | — | 2.47M | 2.47M | 1.17M | 13.7K | 6.76M | 73.11% | ↗ |
| 15 | 2023 | Waleed H. Hassanein, M.D. President and Chief Executive Officer | 633.8K | — | 2.47M | 2.47M | 1.17M | 13.7K | 6.76M | 73.11% | ↗ |
| 16 | 2023 | Stephen Gordon Chief Financial Officer | 446.0K | — | 864.3K | 866.1K | 450.0K | 13.7K | 2.64M | 65.55% | ↗ |
| 17 | 2023 | Stephen Gordon Former Chief Financial Officer | 446.0K | — | 864.3K | 866.1K | 450.0K | 13.7K | 2.64M | 65.55% | ↗ |
| 18 | 2023 | Tamer Khayal, M.D. Former Chief Commercial Officer | 446.0K | — | 864.3K | 866.1K | 450.0K | 4.1K | 2.63M | 65.78% | ↗ |
| 19 | 2023 | Tamer Khayal, M.D. Chief Commercial Officer | 446.0K | — | 864.3K | 866.1K | 450.0K | 4.1K | 2.63M | 65.78% | ↗ |
| 20 | 2023 | Nick Corcoran Senior Vice President of Supply Chain and Operations | 338.9K | 100.0K | 851.8K | 853.6K | 300.0K | 73.1K | 2.52M | 67.74% | ↗ |
| 21 | 2023 | Nicholas Corcoran Senior Vice President of Supply Chain and Operations | 338.9K | 100.0K | 851.8K | 853.6K | 300.0K | 73.1K | 2.52M | 67.74% | ↗ |
| 22 | 2023 | Anil Ranganath Senior Vice President, General Counsel and Corporate Secretary | 215.4K | — | 893.0K | 893.8K | 180.0K | 5.2K | 2.19M | 81.69% | ↗ |
| 23 | 2023 | Anil Ranganath Former Senior Vice President, General Counsel and Corporate Secretary | 215.4K | — | 893.0K | 893.8K | 180.0K | 5.2K | 2.19M | 81.69% | ↗ |
| 24 | 2022 | Waleed Hassanein, M.D. President and Chief Executive Officer | 575.2K | — | — | 1.83M | 886.8K | — | 3.29M | 55.53% | ↗ |
| 25 | 2022 | Waleed H. Hassanein, M.D. President and Chief Executive Officer | 575.2K | — | — | 1.83M | 886.8K | — | 3.29M | 55.53% | ↗ |
| 26 | 2022 | Tamer Khayal, M.D. Chief Commercial Officer | 421.9K | — | — | 379.8K | 326.9K | — | 1.13M | 33.65% | ↗ |
| 27 | 2022 | Stephen Gordon Former Chief Financial Officer | 417.7K | — | — | 379.8K | 326.9K | — | 1.12M | 33.78% | ↗ |
| 28 | 2022 | Stephen Gordon Chief Financial Officer | 417.7K | — | — | 379.8K | 326.9K | — | 1.12M | 33.78% | ↗ |
| 29 | 2022 | Miriam Provost, Ph.D. Vice President of Global Regulatory Affairs | 337.2K | — | — | 277.5K | 198.7K | — | 813.5K | 34.12% | ↗ |
| 30 | 2022 | Laura Damme Vice President, Clinical Affairs | 304.5K | — | — | 277.5K | 187.0K | — | 769.1K | 36.09% | ↗ |
| 31 | 2021 | Waleed Hassanein, M.D. President and Chief Executive Officer | 535.0K | — | — | 6.38M | 457.4K | — | 7.37M | 86.53% | ↗ |
| 32 | 2021 | Tamer Khayal, M.D. Chief Commercial Officer | 386.3K | — | — | 1.44M | 165.1K | — | 1.99M | 72.31% | ↗ |
| 33 | 2021 | Stephen Gordon Chief Financial Officer | 370.8K | — | — | 1.44M | 158.5K | — | 1.97M | 73.12% | ↗ |
| 34 | 2021 | Miriam Provost, Ph.D. Vice President of Global Regulatory Affairs | 329.6K | — | — | 514.4K | 109.6K | — | 953.5K | 53.94% | ↗ |
| 35 | 2021 | Laura Damme Vice President, Clinical Affairs | 262.5K | — | — | 514.4K | 74.8K | — | 851.7K | 60.39% | ↗ |
| 36 | 2020 | Waleed Hassanein, M.D. President and Chief Executive Officer | 533.6K | 406.1K | — | 1.45M | — | — | 2.39M | 60.61% | ↗ |
| 37 | 2020 | Tamer Khayal, M.D. Chief Commercial Officer | 385.9K | 147.7K | — | 405.5K | — | — | 939.2K | 43.17% | ↗ |
| 38 | 2020 | Stephen Gordon Chief Financial Officer | 370.5K | 141.8K | — | 405.5K | — | — | 917.8K | 44.18% | ↗ |
| 39 | 2019 | Waleed Hassanein, M.D. President and Chief Executive Officer | 448.6K | 360.2K | — | 2.35M | — | — | 3.16M | 74.40% | ↗ |
| 40 | 2019 | Tamer Khayal, M.D. Chief Commercial Officer | 353.8K | 168.8K | — | 528.9K | — | — | 1.05M | 50.30% | ↗ |
| 41 | 2019 | Stephen Gordon Chief Financial Officer | 329.9K | 162.0K | — | — | — | — | 491.9K | 0.00% | ↗ |
| 42 | 2018 | Waleed Hassanein, M.D. President and Chief Executive Officer | 384.0K | 140.0K | — | — | — | — | 524.0K | 0.00% | ↗ |
| 43 | 2018 | Tamer Khayal, M.D. Chief Commercial Officer | 315.0K | 100.8K | — | — | — | — | 415.8K | 0.00% | ↗ |
| 44 | 2018 | Stephen Gordon Chief Financial Officer | 275.0K | 96.3K | — | — | — | — | 371.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Waleed H. Hassanein | Founder, President, Chief Executive Officer & Director | 2M | — |
| Tamer I. Khayal | Senior Vice President of International | 1M | — |
| Gerardo Hernandez | Chief Financial Officer & Treasurer | 1M | male |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | 865.8K | male |
| Anil Ranganath | Advisor | 634.8K | male |
| Matthew Forsyth | Senior Vice President, General Counsel & Corporate Secretary | 594.3K | male |
| Miriam C. Provost | Vice President of Global Regulatory Affairs | 535.9K | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TMDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
